Aug 27, 2025 • Benzinga
SOMEWHAT-BULLISH
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference - ProKidney ( NASDAQ:PROK )
WINSTON-SALEM, N.C., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- ProKidney Corp. PROK ( "ProKidney" or the "Company" ) , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease ( CKD ) , today announced that senior members of the management team will be participating ...
Aug 27, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
WINSTON-SALEM, N.C., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- ProKidney Corp. ( Nasdaq: PROK ) ( "ProKidney" or the "Company" ) , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease ( CKD ) , today announced that senior members of the management team will be ...
Aug 19, 2025 • Benzinga
NEUTRAL
Chamath Palihapitiya Returns To SPACs: Past 18 Deals, Investments Average Loss Of 14% - Lemonade ( NYSE:LMND ) , Clover Health Investments ( NASDAQ:CLOV )
Chamath Palihapitiya is back with a new SPAC filing. A look back at the 18 SPACs Chamath Palihapitiya has been involved with and the return for investors. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here →
Aug 13, 2025 • Motley Fool
SOMEWHAT-BULLISH
ProKidney Reports 78 Percent Gain in Q2
ProKidney ( NASDAQ:PROK ) , a biopharmaceutical company developing cell therapies for chronic kidney disease ( CKD ) , released its second quarter results on August 12, 2025. The main focus of the release was encouraging clinical updates for its lead product rilparencel, especially from the Phase ...
Jul 22, 2025 • Motley Fool
NEUTRAL
Meet the Biotech Stock That Rocketed 775% Higher
If you're looking for stocks that can make dramatic movements in a short time frame, the biotechnology space has what you crave. At the end of June, ProKidney ( NASDAQ: PROK ) stock was languishing at less than $1 per share. When the market closed on July 10, the stock was trading at $5.18 per ...
Jul 17, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
PROKIDNEY CP ( PROK ) Upgraded to Strong Buy: What Does It Mean for the Stock?
PROKIDNEY CP (PROK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).